FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971837761> ?p ?o ?g. }

• W2971837761 endingPage "857" @default.
• W2971837761 startingPage "848" @default.
• W2971837761 abstract "SUMMARY Background There has been limited evaluation of the association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases (IBD). Aim To perform a systematic review and meta‐analysis to evaluate the potential role of therapeutic drug monitoring (TDM) for vedolizumab. Methods Through a systematic literature search through 28 February 2019, we identified five cohort studies (558 patients, 42% with ulcerative colitis) reporting the association between vedolizumab trough concentration and clinical outcomes in patients with IBD. We calculated mean difference (MD) in vedolizumab trough concentration in patients achieving vs not achieving clinical outcomes, and qualitatively synthesized thresholds associated with favourable outcomes. Results In patients with UC, median vedolizumab trough concentrations were consistently higher in patients achieving clinical remission (median, 14.3 μg/mL vs 10.5 μg/mL; MD, 5.1 μg/mL, 95% CI, 2.8‐7.4) or endoscopic remission (median, 13.0 μg/mL vs 9.7; MD, 5.1 μg/mL, 95% CI, 2.2‐7.9). In patients with CD, there was no significant difference in median vedolizumab trough concentrations in patients achieving vs not achieving clinical remission (MD, 2.0 μg/mL; 95% CI, −0.5 to 4.5) or endoscopic remission (MD, 3.6 μg/mL; 95% CI, −1.4 to 8.6). In patients with UC, week 6 vedolizumab trough concentrations ≥18.5‐20.8 μg/mL, and maintenance trough concentrations ≥9.0‐12.6 μg/mL were associated with favourable clinical outcomes. Antibodies to vedolizumab were reported in 1.7%‐3.0% patients on maintenance therapy. Conclusion Based on meta‐analysis, patients with UC who achieve endoscopic and clinical remission have significantly higher vedolizumab trough concentration during maintenance therapy. Vedolizumab trough concentration >20 μg/mL at week 6, and >12 μg/mL during maintenance may be associated with better outcomes, though cause‐effect relationship remains unclear. Prospective studies on reactive and proactive therapeutic drug monitoring of vedolizumab (vs empiric dose escalation) are warranted." @default.
• W2971837761 created "2019-09-12" @default.
• W2971837761 creator A5016530589 @default.
• W2971837761 creator A5025171267 @default.
• W2971837761 creator A5032150391 @default.
• W2971837761 creator A5035847062 @default.
• W2971837761 creator A5052596220 @default.
• W2971837761 creator A5056035336 @default.
• W2971837761 creator A5068268866 @default.
• W2971837761 date "2019-09-04" @default.
• W2971837761 modified "2023-10-13" @default.
• W2971837761 title "Systematic review with meta‐analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases" @default.
• W2971837761 cites W1968331553 @default.
• W2971837761 cites W1968655366 @default.
• W2971837761 cites W1995864039 @default.
• W2971837761 cites W2005501262 @default.
• W2971837761 cites W2023078169 @default.
• W2971837761 cites W2036740 @default.
• W2971837761 cites W2054580584 @default.
• W2971837761 cites W2077531651 @default.
• W2971837761 cites W2107328434 @default.
• W2971837761 cites W2125435699 @default.
• W2971837761 cites W2126930838 @default.
• W2971837761 cites W2162805528 @default.
• W2971837761 cites W2556146932 @default.
• W2971837761 cites W2589422996 @default.
• W2971837761 cites W2615644319 @default.
• W2971837761 cites W2741466972 @default.
• W2971837761 cites W2744879509 @default.
• W2971837761 cites W2764071025 @default.
• W2971837761 cites W2773289068 @default.
• W2971837761 cites W2792406291 @default.
• W2971837761 cites W2799380236 @default.
• W2971837761 cites W2801753207 @default.
• W2971837761 cites W2809296974 @default.
• W2971837761 cites W2888701558 @default.
• W2971837761 cites W2895526782 @default.
• W2971837761 cites W2911819327 @default.
• W2971837761 cites W2923576761 @default.
• W2971837761 cites W4296224660 @default.
• W2971837761 doi "https://doi.org/10.1111/apt.15484" @default.
• W2971837761 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7083298" @default.
• W2971837761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31483522" @default.
• W2971837761 hasPublicationYear "2019" @default.
• W2971837761 type Work @default.
• W2971837761 sameAs 2971837761 @default.
• W2971837761 citedByCount "32" @default.
• W2971837761 countsByYear W29718377612019 @default.
• W2971837761 countsByYear W29718377612020 @default.
• W2971837761 countsByYear W29718377612021 @default.
• W2971837761 countsByYear W29718377612022 @default.
• W2971837761 countsByYear W29718377612023 @default.
• W2971837761 crossrefType "journal-article" @default.
• W2971837761 hasAuthorship W2971837761A5016530589 @default.
• W2971837761 hasAuthorship W2971837761A5025171267 @default.
• W2971837761 hasAuthorship W2971837761A5032150391 @default.
• W2971837761 hasAuthorship W2971837761A5035847062 @default.
• W2971837761 hasAuthorship W2971837761A5052596220 @default.
• W2971837761 hasAuthorship W2971837761A5056035336 @default.
• W2971837761 hasAuthorship W2971837761A5068268866 @default.
• W2971837761 hasBestOaLocation W29718377613 @default.
• W2971837761 hasConcept C112705442 @default.
• W2971837761 hasConcept C126322002 @default.
• W2971837761 hasConcept C201903717 @default.
• W2971837761 hasConcept C2776207728 @default.
• W2971837761 hasConcept C2777288759 @default.
• W2971837761 hasConcept C2778260677 @default.
• W2971837761 hasConcept C2779134260 @default.
• W2971837761 hasConcept C2780272996 @default.
• W2971837761 hasConcept C2780479503 @default.
• W2971837761 hasConcept C2909675724 @default.
• W2971837761 hasConcept C2910800852 @default.
• W2971837761 hasConcept C2911091166 @default.
• W2971837761 hasConcept C31785415 @default.
• W2971837761 hasConcept C71924100 @default.
• W2971837761 hasConcept C72563966 @default.
• W2971837761 hasConcept C90924648 @default.
• W2971837761 hasConceptScore W2971837761C112705442 @default.
• W2971837761 hasConceptScore W2971837761C126322002 @default.
• W2971837761 hasConceptScore W2971837761C201903717 @default.
• W2971837761 hasConceptScore W2971837761C2776207728 @default.
• W2971837761 hasConceptScore W2971837761C2777288759 @default.
• W2971837761 hasConceptScore W2971837761C2778260677 @default.
• W2971837761 hasConceptScore W2971837761C2779134260 @default.
• W2971837761 hasConceptScore W2971837761C2780272996 @default.
• W2971837761 hasConceptScore W2971837761C2780479503 @default.
• W2971837761 hasConceptScore W2971837761C2909675724 @default.
• W2971837761 hasConceptScore W2971837761C2910800852 @default.
• W2971837761 hasConceptScore W2971837761C2911091166 @default.
• W2971837761 hasConceptScore W2971837761C31785415 @default.
• W2971837761 hasConceptScore W2971837761C71924100 @default.
• W2971837761 hasConceptScore W2971837761C72563966 @default.
• W2971837761 hasConceptScore W2971837761C90924648 @default.
• W2971837761 hasFunder F4320306301 @default.
• W2971837761 hasFunder F4320310104 @default.
• W2971837761 hasFunder F4320337357 @default.
• W2971837761 hasIssue "8" @default.
• W2971837761 hasLocation W29718377611 @default.

• next